Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$0.89 +1.9%	$0.84	$0.55 ▼ $1.66	$115.48M	0.92	767,866 shs	182,375 shs
CRDL Cardiol Therapeutics	$1.46 -1.0%	$1.21	$0.77 ▼ $2.63	$120.26M	1.03	309,509 shs	28,853 shs
FBLG FibroBiologics	$0.72 +1.7%	$0.91	$0.69 ▼ $6.06	$27.70M	-0.8	299,935 shs	75,464 shs
QNTM Quantum Biopharma	$23.62 +11.8%	$13.61	$2.70 ▼ $38.25	$68.57M	0.55	936,830 shs	162,489 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	+1.81%	+9.24%	+4.45%	+26.03%	-16.44%
CRDL Cardiol Therapeutics	+1.38%	+11.36%	+26.72%	+53.13%	-28.29%
FBLG FibroBiologics	-1.15%	-0.84%	-12.32%	-25.05%	-84.14%
QNTM Quantum Biopharma	-13.34%	-30.02%	+82.54%	+146.73%	+2,111,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATOS Atossa Genetics	2.1491 of 5 stars	3.7	1.0	0.0	0.0	3.3	1.7	0.0
CRDL Cardiol Therapeutics	2.5107 of 5 stars	3.7	2.0	0.0	0.0	4.0	0.0	0.6
FBLG FibroBiologics	2.6503 of 5 stars	3.6	2.0	0.0	0.0	2.2	2.5	0.6
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	3.33	Buy	$6.17	589.78% Upside
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	449.83% Upside
FBLG FibroBiologics	3.20	Buy	$13.00	1,695.58% Upside
QNTM Quantum Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest FBLG, CRDL, ATOS, and QNTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	QNTM Quantum Biopharma	Singular Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
6/17/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/6/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.25 ➝ $7.50
6/5/2025	ATOS Atossa Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$4.00
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
5/15/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/21/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.25
4/16/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/9/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/7/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/1/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$0.57 per share	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.22 per share	N/A
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$0.08 per share	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$4.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$25.50M	-$0.21	N/A	N/A	N/A	N/A	-33.90%	-31.53%	8/11/2025 (Estimated)
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-209.63%	-141.09%	7/14/2025 (Estimated)
FBLG FibroBiologics	-$11.16M	-$0.21	N/A	N/A	N/A	N/A	-1,022.04%	-117.56%	8/6/2025 (Estimated)
QNTM Quantum Biopharma	-$14.20M	-$15.98	N/A	N/A	N/A	N/A	-155.20%	-94.90%	8/13/2025 (Estimated)

Latest FBLG, CRDL, ATOS, and QNTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	QNTM Quantum Biopharma	-$0.37	-$1.41	-$1.04	-$3.53	$2.09 million	$2.09 million
5/13/2025	Q1 2025	ATOS Atossa Genetics	-$0.06	-$0.05	+$0.01	-$0.05	N/A	N/A
5/13/2025	Q1 2025	FBLG FibroBiologics	-$0.10	-$0.14	-$0.04	-$0.14	N/A	N/A
3/31/2025	Q4 2024	CRDL Cardiol Therapeutics	-$0.08	-$0.07	+$0.01	-$0.07	N/A	N/A
3/31/2025	Q4 2024	FBLG FibroBiologics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
3/28/2025	Q4 2024	QNTM Quantum Biopharma	-$0.80	-$2.89	-$2.09	-$2.89	$0.92 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	12.67	12.67
CRDL Cardiol Therapeutics	0.01	3.26	3.26
FBLG FibroBiologics	N/A	1.14	1.14
QNTM Quantum Biopharma	N/A	0.96	0.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
CRDL Cardiol Therapeutics	12.49%
FBLG FibroBiologics	N/A
QNTM Quantum Biopharma	1.24%

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	7.60%
CRDL Cardiol Therapeutics	5.25%
FBLG FibroBiologics	20.00%
QNTM Quantum Biopharma	8.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	8	129.17 million	119.35 million	Optionable
CRDL Cardiol Therapeutics	20	82.65 million	78.31 million	Not Optionable
FBLG FibroBiologics	10	38.26 million	30.61 million	N/A
QNTM Quantum Biopharma	N/A	2.91 million	2.66 million	N/A

FBLG, CRDL, ATOS, and QNTM Headlines

Recent News About These Companies

Best Cannabis Stocks To Watch Today - June 26th

June 26 at 2:04 PM | marketbeat.com

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering

June 26 at 7:30 AM | globenewswire.com

Cannabis Stocks To Research - June 25th

June 25 at 2:24 PM | marketbeat.com

Q1 Earnings Forecast for QNTM Issued By Singular Research

June 24 at 2:41 AM | americanbankingnews.com

Top Cannabis Stocks To Keep An Eye On - June 23rd

June 23, 2025 | marketbeat.com

What is Singular Research's Estimate for QNTM Q1 Earnings?

June 23, 2025 | marketbeat.com

Quantum Biopharma (NASDAQ:QNTM) Upgraded at Singular Research

June 21, 2025 | marketbeat.com

Cannabis Stocks To Follow Today - June 20th

June 20, 2025 | marketbeat.com

Unbuzzd Wellness Inc Ordinary Shares - Class B (Sub Voting)

June 19, 2025 | morningstar.comM

Quantum, CyberCatch, Kodiak at 52-Week Highs on News

June 18, 2025 | ca.finance.yahoo.com

Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress

June 18, 2025 | newsfilecorp.comN

Keg, LQWD, Quantum at 52-Week Highs on News

June 17, 2025 | baystreet.ca

Cannabis Stocks To Add to Your Watchlist - June 17th

June 17, 2025 | marketbeat.com

Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital

June 17, 2025 | globenewswire.com

Quantum BioPharma plans special dividend tied to legal action

June 14, 2025 | investing.com

Best Cannabis Stocks To Add to Your Watchlist - June 13th

June 13, 2025 | marketbeat.com

Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds

June 13, 2025 | globenewswire.com

Quantum BioPharma Boosts Digital Asset Holdings to $5 Million with New Bitcoin Purchase

June 10, 2025 | bitcoinmagazine.com

Quantum BioPharma clarifies misinformation on stock name, RTO rumors

June 4, 2025 | investing.com

Quantum BioPharma Clarifies Name Confusion, Refutes RTO Rumors With Unbuzzd Wellness

June 4, 2025 | nasdaq.com

Quantum BioPharma Clarifies It Has Not Changed Its Name

June 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG, CRDL, ATOS, and QNTM Company Descriptions

Atossa Genetics NASDAQ:ATOS

$0.89 +0.02 (+1.89%)

As of 11:43 AM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Cardiol Therapeutics NASDAQ:CRDL

$1.46 -0.02 (-1.02%)

As of 11:41 AM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

FibroBiologics NASDAQ:FBLG

$0.72 +0.01 (+1.69%)

As of 11:42 AM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Quantum Biopharma NASDAQ:QNTM

$23.62 +2.50 (+11.81%)

As of 11:42 AM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time